<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33975372</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1438-8685</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Laryngo- rhino- otologie</Title><ISOAbbreviation>Laryngorhinootologie</ISOAbbreviation></Journal><ArticleTitle>[Acute facial paresis as a possible complication of vaccination against SARS-CoV-2].</ArticleTitle><Pagination><StartPage>526</StartPage><EndPage>528</EndPage><MedlinePgn>526-528</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-1501-0470</ELocationID><Abstract><AbstractText>Although acute facial nerve palsy (Bell's palsy) is explicitly mentioned in the information sheets for vaccines as a possible complication of vaccination against SARS-CoV-2, from our point of view the benefits of the vaccination clearly outweigh the possible risks. At most, if at all, a slightly increased risk can be derived from the previous case reports. In general, the risk of acute facial palsy is described in association with many vaccinations. The risk, if any, does not appear to be a specific risk of SARS-CoV-2 vaccines. On the other hand, cases of acute facial palsy as symptom of a COVID-19 disease have also been described, so that the theoretical question arises as to the extent to which the vaccination may prevent rather than promote the occurrence of facial palsy. Ultimately, if acted quickly, acute facial paralysis can be treated well and its severity and sequelae cannot be compared with the severity of a COVID-19 disease and its possible long-COVID sequelae.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volk</LastName><ForeName>Gerd Fabian</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik f&#xfc;r Hals-Nasen-Ohrenheilkunde und Fazialis-Nerv-Zentrum, Universit&#xe4;tsklinikum Jena.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuttenreich</LastName><ForeName>Anna-Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik f&#xfc;r Hals-Nasen-Ohrenheilkunde und Fazialis-Nerv-Zentrum, Universit&#xe4;tsklinikum Jena.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geitner</LastName><ForeName>Maren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik f&#xfc;r Hals-Nasen-Ohrenheilkunde und Fazialis-Nerv-Zentrum, Universit&#xe4;tsklinikum Jena.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guntinas-Lichius</LastName><ForeName>Orlando</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik f&#xfc;r Hals-Nasen-Ohrenheilkunde und Fazialis-Nerv-Zentrum, Universit&#xe4;tsklinikum Jena.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Eine akute Fazialisparese als m&#xf6;gliche Impfkomplikation bei einer Impfung gegen SARS-CoV-2.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Laryngorhinootologie</MedlineTA><NlmUniqueID>8912371</NlmUniqueID><ISSNLinking>0935-8943</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020330" MajorTopicYN="Y">Bell Palsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005154" MajorTopicYN="N">Facial Nerve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005158" MajorTopicYN="Y">Facial Paralysis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Obwohl die akute Fazialisparese (akute Gesichtsnervenl&#xe4;hmung, Bell-L&#xe4;hmung) als m&#xf6;gliche Impfkomplikation auf eine Impfung gegen SARS-CoV-2 explizit im Aufkl&#xe4;rungsmerkblatt der Impfstoffe erw&#xe4;hnt wird, &#xfc;berwiegt aus unserer Sicht klar der Nutzen der Impfung gegen&#xfc;ber m&#xf6;glichen Risiken. Aus den bisherigen Fallbeschreibungen l&#xe4;sst sich allenfalls, wenn &#xfc;berhaupt, ein gering erh&#xf6;htes Risiko ableiten. Das Risiko einer akuten Fazialisparese ist im Zusammenhang mit vielen Impfungen beschrieben; das Risiko scheint, wenn vorhanden, kein spezifisches Risiko zu sein. Andererseits sind auch F&#xe4;lle von akuter Fazialisparese unter einer COVID-19-Erkrankung beschrieben, sodass sich die theoretische Frage stellt, inwieweit die Impfung m&#xf6;glicherweise eher das Auftreten einer Fazialisparese verhindert als bef&#xf6;rdert. Schlussendlich l&#xe4;sst sich die akute Fazialisparese, wenn schnell gehandelt wird, gut therapieren und ist von der Schwere und Folgeerscheinungen nicht mit der Krankheitsschwere und den m&#xf6;glichen Folgeerscheinungen einer COVID-19-Erkrankung zu vergleichen.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></OtherAbstract><CoiStatement>Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33975372</ArticleId><ArticleId IdType="doi">10.1055/a-1501-0470</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>